COLLABORATION AND COMMERCIALIZATION AGREEMENTCollaboration and Commercialization Agreement • November 9th, 2020 • Senseonics Holdings, Inc. • Industrial instruments for measurement, display, and control • New York
THIS COLLABORATION AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is made as of August 9, 2020 (the “Effective Date”) by and between Senseonics Incorporated, a Delaware corporation (“Senseonics”), with its principal office and place of business at 20451 Seneca Meadows Parkway Germantown, MD 20876-7005, and Ascensia Diabetes Care Holdings AG, a Swiss company (“Ascensia” or “ADC”) with its principal office and place of business at Peter Merian-Strasse 90, 4052 Basel, Switzerland (each of Senseonics and Ascensia, a “Party” and together, the “Parties”).
COLLABORATION AND COMMERCIALIZATION AGREEMENTCollaboration and Commercialization Agreement • June 26th, 2006 • Replidyne Inc • Pharmaceutical preparations • New York
CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY ***) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL FIRST AMENDMENT TO...Collaboration and Commercialization Agreement • August 9th, 2021 • Senseonics Holdings, Inc. • Industrial instruments for measurement, display, and control
This First Amendment (the “First Amendment”) to the Collaboration and Commercialization Agreement is entered into by and between Senseonics Incorporated (“Senseonics”) and Ascensia Diabetes Care Holdings AG (“Ascensia”) (each of Senseonics and Ascensia, a “Party”, and together, the “Parties”) and is effective as of March 31, 2021 (the “First Amendment Effective Date”).
COLLABORATION AND COMMERCIALIZATION AGREEMENTCollaboration and Commercialization Agreement • April 5th, 2006 • Replidyne Inc • New York
